Abstracts tagged "gout"

Abstract Number: 1099 • 2016 ACR/ARHP Annual Meeting
Synovial Exosomes Induce Osteoclast Differentiation in Rheumatoid arthritis
Ji Eun Song¹, Ji Hye Shin¹, Ki Won Moon², Se Hui Shon¹, Ji Soo Park³, Eun Bong Lee³, Yeong Wook Song^1,3 and Eun Young Lee³, ¹Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, and College of Medicine or College of Pharmacy, Seoul National University, Seoul, Republic of Korea, Seoul, Korea, The Republic of, ²Department of Internal Medicine, Kangwon National University Hospital, Chuncheon, Republic of Korea, Chuncheon, Korea, The Republic of, ³Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea, Seoul, Korea, The Republic of
Background/Purpose: Exosomes are small membrane vesicles (40-150 nm) of endocytic origin secreted by many types of cells and engage in cell-to-cell communication by transferring proteins,…
Abstract Number: 2300 • 2016 ACR/ARHP Annual Meeting
Tophaceous Gout and the Risk of Mortality: A General Population-Based Study
Hyon K. Choi¹, Leo Lu², Sharan K. Rai^3,4 and Yuqing Zhang⁵, ¹Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Allergy, Immunology, and Rheumatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Arthritis Research Canada, Vancouver, BC, Canada, ⁴Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁵Clinical Epidemiology and Training Unit, Boston University School of Medicine, Boston, MA
Tophaceous Gout and the Risk of Mortality: A General Population-Based Study Background/Purpose: A recent study based on data from a gout specialty clinic (N=706) found…
Abstract Number: 207 • 2016 ACR/ARHP Annual Meeting
Integrated Safety of Lesinurad, a Novel Uric Acid Reabsorption Inhibitor for the Treatment of Gout
Michael A. Becker¹, Robert T. Keenan², Puja Khanna³, Raymond Malamet⁴, Kathleen Bos⁴, Jingyi Li⁴, Jia Hu⁵ and William White⁶, ¹University of Chicago, Chicago, IL, ²Rheumatology, Duke University, Durham, NC, ³Rheumatology, University of Michigan, Ann Arbor, MI, ⁴AstraZeneca Pharmaceuticals, Wilmington, DE, ⁵Ardea Biosciences, Inc., San Diego, CA, ⁶University of Connecticut School of Medicine, Farmington, CT
Background/Purpose: Lesinurad is a selective uric acid reabsorption inhibitor recently approved at 200 mg daily in combination with a xanthine oxidase inhibitor (XOI) for treatment…
Abstract Number: 1242 • 2016 ACR/ARHP Annual Meeting
Rate of Hospitalization for Heart Failure Is Lower in Patients with Controlled Gout Versus Uncontrolled Gout
Robert Morlock¹, Pierre Chevalier² and Alyssa B Klein³, ¹Ardea Biosciences, Inc., San Diego, CA, ²IMS Health, New York, NY, ³AstraZeneca, Gaithersburg, MD
Background/Purpose: Hyperuricemia is associated with worsened outcomes in heart failure (HF) patients. However, little is known regarding the association between gout and HF itself. This…
Abstract Number: 2303 • 2016 ACR/ARHP Annual Meeting
Trends in Gout and Rheumatoid Arthritis Hospitalizations in Canada from 2000-2011
Sharan K. Rai^1,2, J. Antonio Avina-Zubieta^2,3, Natalie McCormick^2,4, Mary A. De Vera^2,5, Diane Lacaille^2,6, Eric C. Sayre² and Hyon K. Choi^7,8, ¹Experimental Medicine, University of British Columbia, Vancouver, BC, Canada, ²Arthritis Research Canada, Richmond, BC, Canada, ³Division of Rheumatology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada, ⁴Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada, ⁵Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada, ⁶Medicine, University of British Columbia, Vancouver, BC, Canada, ⁷Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁸Arthritis Research Canada, Vancouver, BC, Canada
Background/Purpose: Gout and rheumatoid arthritis (RA) are the two most common forms of inflammatory arthritis worldwide. As hospitalizations for both conditions lead to substantial health…
Abstract Number: 208 • 2016 ACR/ARHP Annual Meeting
Examination of Serum Uric Acid (sUA) Lowering and Safety with Extended Lesinurad + Allopurinol Treatment in Subjects with Gout
Kenneth Saag¹, Michael A. Becker², Chris Storgard³, Maple Fung³, Jia Hu³ and Thomas Bardin⁴, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Chicago, Chicago, IL, ³Ardea Biosciences, Inc., San Diego, CA, ⁴Hôpital Lariboisière, Paris, France
Background/Purpose: Two replicate, randomized, core Phase III trials (CLEAR 1 & 2) reported significantly more subjects treated with lesinurad 200 mg (LESU200) or 400 mg…
Abstract Number: 2022 • 2016 ACR/ARHP Annual Meeting
Developing a Gout Needs Assessment Incorporating Patient Perspective on Self-Management, Self-Efficacy and Disease Specific Knowledge, to Inform a Patient Education Initiative
Adam Rifaat¹, Adena Batterman², Roberta Horton² and Theodore R. Fields¹, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Social Work Programs, Hospital for Special Surgery, New York, NY
Background/Purpose: Gout is the most common inflammatory arthritis in adults, with great impact on quality of life. Despite excellent therapeutic options, outcomes remain suboptimal. Research supports…
Abstract Number: 2305 • 2016 ACR/ARHP Annual Meeting
Mapping the Topography of Gout Flares: Solutions for Flare Reporting in Gout Clinical Trials
Novell Teoh¹, Gregory Gamble², Anne Horne², William J. Taylor³, Kate Palmano⁴ and Nicola Dalbeth¹, ¹University of Auckland, Auckland, New Zealand, ²Department of Medicine, University of Auckland, Auckland, New Zealand, ³University of Otago, Wellington, New Zealand, ⁴Consultant Scientist, Waikato, New Zealand
Background/Purpose : Recurrent flares of inflammatory arthritis are the central clinical feature of gout. However, methods of gout flare reporting in research settings are inconsistent…
Abstract Number: 209 • 2016 ACR/ARHP Annual Meeting
Clinical Response of Tophus and Flares to Extended Use of Lesinurad in Combination with a Xanthine Oxidase Inhibitor in Patients with Gout
Thomas Bardin¹, Nicola Dalbeth², Robert Terkeltaub³, Chris Storgard⁴, Maple Fung⁴, Jia Hu⁴ and Fernando Perez-Ruiz⁵, ¹Hôpital Lariboisière, Paris, France, ²University of Auckland, Auckland, New Zealand, ³Medicine-Rheumatology, VA Medical Ctr/University of California San Diego, San Diego, CA, ⁴Ardea Biosciences, Inc., San Diego, CA, ⁵Hospital de Cruces and Biocruces Health Research Institute, Vizcaya, Spain
Background/Purpose: Three randomized, double-blind, Phase III trials reported that greater proportions of patients treated with lesinurad 200 mg (LESU200) or 400 mg (LESU400), combined with…
Abstract Number: 2266 • 2016 ACR/ARHP Annual Meeting
A Melanocortin Fusion Peptide (AQB-565) Optimized for Melanocortin Receptor Engagement Significantly Reduces Inflammation in an In Vivo model of Acute Gout
Ronald Berenson¹, Maura-Ann Matthews¹, Wayne Wallis², Raj Dua¹, Margaret Moore¹, Robert Terkeltaub³ and Christopher Clegg^1,4, ¹Aequus BioPharma, Inc., Seattle, WA, ²Dyad Life Sciences, LLC, Seattle, WA, ³Medicine-Rheumatology, University of California, San Diego, La Jolla, CA, ⁴TRIA Bioscience, Seattle, WA
Background/Purpose: The melanocortins (MCs) are endogenous peptides (including ACTH, α-MSH and γ-MSH), which bind 5 G protein-coupled receptors (MCRs 1 through 5) with varying affinity.…
Abstract Number: 3071 • 2016 ACR/ARHP Annual Meeting
Recombinant Human Proteoglycan-4 (rhPRG4) Inhibits Monosodium Urate (MSU) Crystal Phagocytosis By Human Macrophages and Resultant Inflammatory Response
Marwa Qadri¹, Tannin Schmidt², Khaled Elsaid³ and Gregory Jay⁴, ¹Pharmaceutical Sciences, Massachusetts College of Pharmacy and Health Sciences University, Boston, MA, ²Kinesiology and Schulich School of Engineering, University of Calgary, Calgary, AB, Canada, ³Biomedical and Pharmaceutical Sciences, Chapman University, Irvine, CA, ⁴Emergency Medicine, Brown University, Providence, RI
Background/Purpose: Gout is an inflammatory arthritis caused by precipitation of monosodium urate (MSU) crystals in synovial joints. MSU crystals interact with resident macrophages that…
Abstract Number: 212 • 2016 ACR/ARHP Annual Meeting
Pegloticase Provides Clinical Benefit in Patients with Chronic Refractory Gout Who Did Not Meet the Clinical Trial Biochemical Definition of Response
Brian F. Mandell¹, Michael Weisman², Anthony Yeo³ and Peter E. Lipsky⁴, ¹Rheumatology, Cleveland Clinic, Cleveland, OH, ²Rheumatology, Cedars-Sinai Medical Center, West Hollywood, CA, ³Horizon Pharma, Lake Forest, IL, ⁴AMPEL BioSolutions, Charlottesville, VA
Background/Purpose: Pegloticase is a recombinant uricase conjugated to polyethylene glycol approved for the treatment of chronic refractory gout refractory. The pivotal clinical trials for pegloticase…
Abstract Number: 2268 • 2016 ACR/ARHP Annual Meeting
Fructose Amplifies Inflammatory Potential in Human Monocytic Cells Via Reduction of AMP-Activated Protein Kinase Activity
Xihua Cao¹, Jeffrey N. Miner², Robert Terkeltaub^3,4 and Ru Liu-Bryan^1,4, ¹VA Medical Center, San Diego, CA, ²Discovery Biology, Ardea Biosciences, Inc., San Diego, CA, ³Rheumatology, VA Medical Center, San Diego, CA, ⁴Medicine-Rheumatology, University of California, San Diego, La Jolla, CA
Background/Purpose: High dietary content of fructose (in table sugar, sweetened sodas, energy beverages, and fruit juices) is a substantial risk factor for both hyperuricemia and…
Abstract Number: 3074 • 2016 ACR/ARHP Annual Meeting
Population-Specific Association Between ABCG2 Variants and Tophaceous Disease in People with Gout
Wendy He¹, Amanda Phipps-Green², Lisa K. Stamp³, Tony R. Merriman⁴ and Nicola Dalbeth¹, ¹University of Auckland, Auckland, New Zealand, ²University of Otago, Dunedin, New Zealand, ³University of Otago, Christchurch, New Zealand, ⁴Biochemistry Dept, PO Box 56, University of Otago, Dunedin, New Zealand
Background/Purpose: Tophi contribute to musculoskeletal disability, joint damage and poor health-related quality of life in people with gout. The aim of this study was to…
Abstract Number: 213 • 2016 ACR/ARHP Annual Meeting
Prophylaxis for Infusion Reactions to Pegloticase: An Analyis of Two Different Corticosteroid Pre-Infusion Regimens in US Community Rheumatology Practices
Amar Majjhoo¹, Kome Okposo² and Michael Zdanis³, ¹Shores Rheumatology, St. Clair Shores, MI, ²Horizon Pharma, Lake Forest, IL, ³Cetus Group, LLC, Towson, MD
Background/Purpose: Corticosteroids are commonly utilized, along with other agents in clinical practice for pre-infusion prophylaxis prior to the administration of therapeutic biologic proteins. Two steroids,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].